Researchers have concluded their phase 2 trial of chemotherapy in combination with the drugs nivolumab, and regorafenib. The findings suggest that regorafenib and nivolumab with chemotherapy is safe and demonstrates some anti-tumor activity in patients with advanced oesophagogastric cancer. Based on these results, a randomized phase 3 clinical trial of the combination is planned. In previous studies, each of the drugs has demonstrated potential effectiveness against oesophagogastric adenocarcinoma. Combining these agents was expected to enhance the overall efficacy of the treatment, potentially providing better results. Despite the initial benefits of immunotherapy (like nivolumab) and chemotherapy in treating oesophagogastric cancer, many...